NEW YORK, Oct. 4, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC) announced today that it has been granted a Research Tissue Banking License by the New York State Department of Health. 

Dr. Steven Victor, Chairman and CEO of IntelliCell, stated that "We are very pleased with the Tissue Banking License from New York State.  This brings us closer to the development of autologous and allogenic stromal vascular fraction tissue for researchers around the world.  With the vast amount of clinical research being conducted using adipose derived cellular components, we can fill a supply chain gap that exists today.  This is significant for the Regenerative Medicine industry and those conducting important research resulting in better medicine."

Robert J. Sexauer, Executive Vice President of Clinical Development, added "it has proven very challenging for universities and other researchers to obtain a consistent supply of stromal vascular fraction cells due to HIPPA and other privacy issues.   IntelliCell has developed a patent pending process that utilizes tissue donors as the source for the vascular adipose tissue that is processed into the cellular end product.  We are happy to make an important contribution to the advancement of our technology as it moves from research laboratories and into the clinic".

About IntelliCell BioSciences

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

Forward-Looking Statements

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.


IntelliCell BioSciences, Inc

Contact: Robert J. Sexauer

Phone:  646.576.8706

Email Contact: 

SOURCE IntelliCell BioSciences, Inc.

Copyright 2012 PR Newswire